Article PDF first page preview

First page of A Comprehensive Analysis of Surgically Treated Renal Tumor Characteristics in Turkey: Nationwide Study

Introduction: To evaluate the kidney tumor characteristics in surgically treated patients in Turkey. Methods: Patients who underwent surgical treatment for kidney tumors between January 2017 and December 2022 in Turkey were retrospectively reviewed through the Health Information Systems of the Ministry of Health. Patient’s age, gender, comorbidities, surgical methods, and tumor characteristics were evaluated. Results: The most common subtype of RCC was clear cell RCC(ccRCC) in 4892 patients (72%). Papillary RCC (pRCC) was less frequent in patients under 50, with its incidence increasing with age compared to other subtypes (p=0.006). There was a significant relationship was found between hypertension and pathological subtypes (p=0.002), with pRCC and unclassified RCC contributing to this difference. Among RCC subtypes, as the ISUP/Fuhrman grade increased, the tumor stage also progressed (p<0.001). Tumors in males and tumors in the left kidney were at more advanced cancer at the time of diagnosis (p<0.001 and p=0.006, respectively). In multivariate logistic regression analysis, advanced age (Odds Ratio [OR]: 1.007, 95% Confidence Interval [CI]: 1.001-1.014, p=0.04), male gender (OR:0.416, %95 CI:0.350-0.493, p<0.001), increased tumor size (OR:1.117, 95% CI: 1.079-1.156, p<0.001), and the presence of diabetes mellitus (OR:1.222, 95% CI:1.007-1.483, p=0.042) were found to be independent risk factors for malignancy. Conclusions: Our study identifies key factors associated with surgically treated renal tumors in Turkey. While aligning with prior research, these findings highlight the need for detailed studies to clarify the impact of biological, demographic, and lifestyle factors on RCC risk and progression, enabling more accurate diagnosis and tailored treatment.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.